Munronin V with 7/7/6 tricarbocyclic framework from Munronia henryi harms inhibits tau pathology by activating autophagy. Issue 3 (3rd January 2023)

• Record Type: Journal Article
• Authors: Yan, Ying; Ran, Xiaoqian; Wang, Dan; Zhang, Xiong; Peng, Mingyou; Yan, Xiaoyan; Tang, Lei; Liang, Hong; Qin, Xujie; Di, Ying-Tong; Luo, Rongcan; Hao, Xiao-Jiang; Yao, Yong-Gang
• Is Part Of: Organic & biomolecular chemistry. Volume 21:Issue 3(2023)
• Page Start: 514
• Page End: 519
• Publication Date: 2023-01-03
• Subjects: Chemistry, Organic -- Periodicals; Bioorganic chemistry -- Periodicals; Chemistry, Physical organic -- Periodicals; 547
• DOI: 10.1039/d2ob01965e
• Languages: English
• ISSNs: 1477-0520

Abstract

Abstract : Munronin V (1 ), a limonoid possessing a newly 7/7/6 tricarbocyclic framework, was obtained from Munronia henryi Harms. 1 inhibited Tau pathology by activating TFEB-mediated autophagy, suggesting its potential for against Alzheimer's disease (AD). Abstract : Munronin V (1 ), isolated from Munronia henryi Harms, is the first example, to the best of our knowledge, of an unprecedented 7/7/6 tricarbocyclic framework featuring an unusual A, B- seco -limonoid ring. The structures of munronin V were established from extensive spectroscopic and electronic circular dichroism (ECD) analyses. The novel A, B- seco with two seven-membered lactones was formed as a result of Baeyer–Villiger oxidation. Compound 1 activated autophagy and inhibited Tau pathology as revealed by flow cytometric analyses, confocal imaging analysis and western blotting, and this effect was mediated by transcription factor EB (TFEB). These findings suggested that 1 might have potential as a compound for combating Alzheimer's disease.